Subscribe to RSS
DOI: 10.1055/a-2771-7283
Near-Complete Response After Total Neoadjuvant Therapy: Management Options in the Current Landscape
Authors
Funding Information C.N.Z. was supported by the Washington University School of Medicine Surgical Oncology Basic Science and Translational Research Training Program grant T32 CA009621 from the National Cancer Institute (NCI).
Abstract
Advances in neoadjuvant therapies have led to paradigm shifts in rectal cancer management, particularly increased emphasis on organ preservation through nonoperative management (NOM) with active surveillance. Management of patients with near-complete response (NCR) to neoadjuvant therapy remains controversial, though several centers have incorporated these patients into their NOM protocols. This narrative review aims to summarize the historical context, clinical criteria, treatment options, and outcomes for patients who achieve NCR and initiate organ preservation. We also discuss common pitfalls of applying organ preservation strategies within this population, as well as our institutional management algorithm. NCR describes a robust but partial response to total neoadjuvant therapy with lingering findings such as superficial ulceration, small mucosal nodules, or minimal residual signal on magnetic resonance imaging. Recommended timing of initial restaging is at least 8 to 12 weeks following completion of radiotherapy, with longer intervals allowing more time for progressive tumoricidal effects. Patients with stable NCR or evolution to clinical complete response (CCR) have been offered NOM with organ preservation rates ranging from 40 to 70%. While local regrowths are more common among patients with NCR relative to patients with CCR, they appear to be salvageable with total mesorectal excision with comparable oncologic outcomes to immediate proctectomy. Given higher local regrowth rates among patients with NCR, shared decision-making must be used to ascertain patient preferences and ensure surveillance compliance. We found data on the use of NOM among rectal cancer patients who achieve a NCR are heterogeneous but have demonstrated clinically significant organ preservation rates with acceptable oncologic outcomes. The success of NOM depends on multiple factors, including tumor stage at diagnosis, clinical findings at time of restaging evaluation, and the ability of patients to participate in frequent surveillance at experienced centers. With careful patient selection and use of shared decision-making to weigh the benefits and risks of active surveillance, organ preservation strategies have the potential to minimize morbidity for patients with rectal cancer who achieve NCR.
Publication History
Article published online:
07 January 2026
© 2026. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Habr-Gama A, Perez RO, Nadalin W. et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004; 240 (04) 711-717 , discussion 717–718
- 2 National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. Version 4.2025. NCCN; 2025
- 3 Habr-Gama A, Perez R, Proscurshim I, Gama-Rodrigues J. Complete clinical response after neoadjuvant chemoradiation for distal rectal cancer. Surg Oncol Clin N Am 2010; 19 (04) 829-845
- 4 Habr-Gama A, Lynn PB, Jorge JMN. et al. Impact of organ-preserving strategies on anorectal function in patients with distal rectal cancer following neoadjuvant chemoradiation. Dis Colon Rectum 2016; 59 (04) 264-269
- 5 Lynn PB, Strombom P, Garcia-Aguilar J. Organ-preserving strategies for the management of near-complete responses in rectal cancer after neoadjuvant chemoradiation. Clin Colon Rectal Surg 2017; 30 (05) 395-403
- 6 Beets GL, Figueiredo NL, Habr-Gama A, van de Velde CJH. A new paradigm for rectal cancer: organ preservation: Introducing the International Watch & Wait Database (IWWD). Eur J Surg Oncol 2015; 41 (12) 1562-1564
- 7 van der Valk MJM, Hilling DE, Bastiaannet E. et al; IWWD Consortium. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet 2018; 391 (10139): 2537-2545
- 8 Martens MH, Maas M, Heijnen LA. et al. Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. J Natl Cancer Inst 2016; 108 (12) djw171
- 9 Hupkens BJP, Maas M, Martens MH. et al. Organ preservation in rectal cancer after chemoradiation: should we extend the observation period in patients with a clinical near-complete response?. Ann Surg Oncol 2018; 25 (01) 197-203
- 10 Simpson G, Hopley P, Wilson J. et al. Long-term outcomes of real world ‘watch and wait’ data for rectal cancer after neoadjuvant chemoradiotherapy. Colorectal Dis 2020; 22 (11) 1568-1576
- 11 Temmink SJD, Peeters KCMJ, Bahadoer RR. et al; International Watch & Wait Database (IWWD) Consortium. Watch and wait after neoadjuvant treatment in rectal cancer: comparison of outcomes in patients with and without a complete response at first reassessment in the International Watch & Wait Database (IWWD). Br J Surg 2023; 110 (06) 676-684
- 12 Thompson HM, Omer DM, Lin S. et al; OPRA Consortium. Organ preservation and survival by clinical response grade in patients with rectal cancer treated with total neoadjuvant therapy: a secondary analysis of the OPRA randomized clinical trial. JAMA Netw Open 2024; 7 (01) e2350903
- 13 Zivanov CN, Kau NS, Nalluri-Butz H. et al. Nonoperative management of rectal cancer: is “near-complete” response safe to surveil?. Ann Surg Oncol 2025; 32 (07) 4922-4930
- 14 Rosen RY, Bercz AP, Omer DM. et al. Correlation between grade of clinical response to neoadjuvant therapy for rectal cancer and oncologic outcomes in the era of watch-and-wait. Dis Colon Rectum 2025; 68 (03) 300-307
- 15 Bahadoer RR, Dijkstra EA, van Etten B. et al; RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (01) 29-42
- 16 Cercek A, Roxburgh CSD, Strombom P. et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol 2018; 4 (06) e180071
- 17 Kasi A, Abbasi S, Handa S. et al. Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis. JAMA Netw Open 2020; 3 (12) e2030097
- 18 Habr-Gama A, Sabbaga J, Gama-Rodrigues J. et al. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management?. Dis Colon Rectum 2013; 56 (10) 1109-1117
- 19 Smith FM, Chang KH, Sheahan K, Hyland J, O'Connell PR, Winter DC. The surgical significance of residual mucosal abnormalities in rectal cancer following neoadjuvant chemoradiotherapy. Br J Surg 2012; 99 (07) 993-1001
- 20 Smith FM, Wiland H, Mace A, Pai RK, Kalady MF. Clinical criteria underestimate complete pathological response in rectal cancer treated with neoadjuvant chemoradiotherapy. Dis Colon Rectum 2014; 57 (03) 311-315
- 21 Smith JJ, Chow OS, Gollub MJ. et al; Rectal Cancer Consortium. Organ preservation in rectal adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer 2015; 15: 767
- 22 Fokas E, Appelt A, Glynne-Jones R. et al. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nat Rev Clin Oncol 2021; 18 (12) 805-816
- 23 Benson AB, Venook AP, Adam M. , et al. NCCN Guidelines Insights: Rectal Cancer, Version 3. 2024 . Published online August 1, 2024.
- 24 Francois Y, Nemoz CJ, Baulieux J. et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999; 17 (08) 2396
- 25 Foster JD, Jones EL, Falk S, Cooper EJ, Francis NK. Timing of surgery after long-course neoadjuvant chemoradiotherapy for rectal cancer: a systematic review of the literature. Dis Colon Rectum 2013; 56 (07) 921-930
- 26 Probst CP, Becerra AZ, Aquina CT. et al; Consortium for Optimizing the Surgical Treatment of Rectal Cancer (OSTRiCh). Extended intervals after neoadjuvant therapy in locally advanced rectal cancer: the key to improved tumor response and potential organ preservation. J Am Coll Surg 2015; 221 (02) 430-440
- 27 Petrelli F, Sgroi G, Sarti E, Barni S. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg 2016; 263 (03) 458-464
- 28 Macchia G, Gambacorta MA, Masciocchi C. et al. Time to surgery and pathologic complete response after neoadjuvant chemoradiation in rectal cancer: A population study on 2094 patients. Clin Transl Radiat Oncol 2017; 4: 8-14
- 29 Custers PA, Beets GL, Bach SP. et al. An international expert-based consensus on the definition of a clinical near-complete response after neoadjuvant (chemo)radiotherapy for rectal cancer. Dis Colon Rectum 2024; 67 (06) 782-795
- 30 Garcia-Aguilar J, Patil S, Gollub MJ. et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 2022; 40 (23) 2546-2556
- 31 Perez RO, Habr-Gama A, Pereira GV. et al. Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer?. Colorectal Dis 2012; 14 (06) 714-720
- 32 Smith FM, Wiland H, Mace A, Pai RK, Kalady MF. Depth and lateral spread of microscopic residual rectal cancer after neoadjuvant chemoradiation: implications for treatment decisions. Colorectal Dis 2014; 16 (08) 610-615
- 33 Habr-Gama A, São Julião GP, Fernandez LM. et al. Achieving a complete clinical response after neoadjuvant chemoradiation that does not require surgical resection: it may take longer than you think!. Dis Colon Rectum 2019; 62 (07) 802-808
- 34 Williams H, Thompson HM, Lin ST. et al; OPRA Consortium. Endoscopic predictors of residual tumor after total neoadjuvant therapy: a post hoc analysis from the organ preservation in rectal adenocarcinoma trial. Dis Colon Rectum 2024; 67 (03) 369-376
- 35 You YN, Baxter NN, Stewart A, Nelson H. Is the increasing rate of local excision for stage I rectal cancer in the United States justified? A nationwide cohort study from the National Cancer Database. Ann Surg 2007; 245 (05) 726-733
- 36 Sajid MS, Farag S, Leung P, Sains P, Miles WFA, Baig MK. Systematic review and meta-analysis of published trials comparing the effectiveness of transanal endoscopic microsurgery and radical resection in the management of early rectal cancer. Colorectal Dis 2014; 16 (01) 2-14
- 37 van Oostendorp SE, Smits LJH, Vroom Y. et al. Local recurrence after local excision of early rectal cancer: a meta-analysis of completion TME, adjuvant (chemo)radiation, or no additional treatment. Br J Surg 2020; 107 (13) 1719-1730
- 38 Nash GM, Weiser MR, Guillem JG. et al. Long-term survival after transanal excision of T1 rectal cancer. Dis Colon Rectum 2009; 52 (04) 577-582
- 39 Garcia-Aguilar J, Renfro LA, Chow OS. et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol 2015; 16 (15) 1537-1546
- 40 Li J, Ma Y, Wen L, Zhang G, Yao X. Outcomes after the watch-and-wait strategy and local excision treatment for rectal cancer: a meta-analysis. Expert Rev Anticancer Ther 2023; 23 (05) 555-564
- 41 Rubens M, Oduyale O, Eltahir AA. et al. “Watch-and-wait” or “lost to follow-up”? adherence to nonoperative management of rectal cancer. J Surg Res 2025; 311: 273-279
- 42 Stacey D, Lewis KB, Smith M. et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2024; 1 (01) CD001431
- 43 Smets L, Debucquoy A, Oldenburger E. et al. Development of a patient decision aid for rectal cancer patients with clinical complete response after neo-adjuvant treatment. Cancers (Basel) 2023; 15 (03) 806
- 44 Abelson JS, Gaetani RS, Hawkins AT. Shared decision making in the treatment of rectal cancer. J Clin Med 2025; 14 (07) 2255
